Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Broncus Holding Corp. ( (HK:2216) ) has provided an announcement.
Broncus Holding Corporation announced that its BroncTarget® Targeted Lung Denervation Radiofrequency Ablation System has been accepted into China’s National Medical Products Administration Innovative Medical Device Special Review Procedure, signaling regulatory recognition of the product’s technological originality and potential clinical value in treating moderate to severe COPD. The system uses a bronchoscopy-based, radiofrequency-driven approach to targeted lung denervation, combining multi-electrode design, adjustable loop diameter, differentiated energy output, and real-time monitoring to enhance efficacy and safety, and its confirmatory clinical trial is currently underway with patient recruitment progressing across 28 hospitals nationwide, underscoring the company’s push to expand its therapeutic portfolio in advanced COPD management, albeit with no guarantee of eventual commercialization.
The most recent analyst rating on (HK:2216) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Broncus Holding Corp. stock, see the HK:2216 Stock Forecast page.
More about Broncus Holding Corp.
Broncus Holding Corporation is a medical device company focused on interventional pulmonology, developing minimally invasive technologies and systems for the diagnosis and treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD), with a particular emphasis on the Chinese healthcare market.
Average Trading Volume: 779,646
Technical Sentiment Signal: Buy
Current Market Cap: HK$1.27B
See more data about 2216 stock on TipRanks’ Stock Analysis page.